Iguña, a leading company in the development of innovative pharmaceutical technologies, has been distinguished with the Innovative Company award in the second edition of the “Reconeixements Empresarials de PIMEC Vallès Occidental”.
This prestigious award was presented by the president of PIMEC, Antoni Cañete, the president of PIMEC Vallès Occidental, Xavier Pujol, the first deputy mayor and councilor of Industry and Enterprise of the City of Terrassa, Maise Balcells, and the secretary of Enterprise and Competitiveness of the Generalitat de Catalunya, Albert Castellanos Maduell.
A recognition for Innovation
The jury of the Reconeixements Empresarials de PIMEC Vallès Occidental highlighted Iguña as a firm “leader in the development of innovative pharmaceutical technologies, contributing significantly to the sector with advanced solutions for the pharmaceutical industry”.
This recognition underscores our ongoing commitment to innovation and excellence in each of our projects.
Support to SMEs
We thank PIMEC not only for this recognition, but also for its tireless work in supporting small and medium-sized enterprises (SMEs).
PIMEC’s mission to foster innovation and competitiveness in the Catalan business fabric is an inspiration to all of us at Iguña.
Dedication and commitment
This award is a testament to the hard work and dedication of our entire team.
From our engineers to our support staff, every member of Iguña has contributed their passion and commitment to make our innovations a reality. We would like to express our deepest gratitude to all of them for their effort and dedication.
The trust of our customers
We would also like to thank our customers, whose trust in our solutions drives us to continue improving.
The satisfaction of our customers is our main motivation and this recognition encourages us to continue working with even more commitment and dedication.
Looking to the future
At Iguña, we believe that innovation is key to progress.
This recognition from PIMEC Vallès Occidental motivates us to continue exploring new frontiers and developing technologies that not only meet the current needs of the pharmaceutical sector, but also anticipate and respond to future challenges.
